Upstream Bio, Inc./$UPB
1D1W1MYTD1Y5YMAX
Capital at risk
About Upstream Bio, Inc.
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. Verekitug has advanced into three separate world-wide, placebo-controlled, randomized Phase 2 clinical trials, two completed in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, and one ongoing in chronic obstructive pulmonary disease (COPD).
- Ticker
- $UPB
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 75
- Headquarters
- Waltham, United States
- Website
- upstreambio.com
UPB Metrics
BasicAdvanced
$318M
-
-$2.89
-
-
Price and volume
Market cap
$318M
52-week high
$33.68
52-week low
$5.65
Average daily volume
654K
Financial strength
Current ratio
27.994
Quick ratio
26.377
Long term debt to equity
0.001
Total debt to equity
0.004
Profitability
EBITDA (TTM)
-169.782
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-4,955.67%
Operating margin (TTM)
-5,382.65%
Revenue per employee (TTM)
$40,000
Management effectiveness
Return on assets (TTM)
-30.28%
Return on equity (TTM)
-46.05%
Valuation
Price to revenue (TTM)
99.773
Price to book
1.17
Price to tangible book (TTM)
1.17
Price to free cash flow (TTM)
-2.309
Free cash flow yield (TTM)
-43.31%
Free cash flow per share (TTM)
-2.516
Growth
Revenue change (TTM)
15.98%
Earnings per share change (TTM)
-4.60%
Bulls say / Bears say
Upstream Bio’s Phase 2 VALIANT trial in severe asthma demonstrated significant improvements in asthma exacerbation rates and lung function, underpinning accelerated progression to Phase 3 studies slated for Q1 2027 (Yahoo Finance)
In the Phase 2 VIBRANT trial for chronic rhinosinusitis with nasal polyps, verekitug achieved clinically meaningful nasal polyp score improvements in approximately 79% of treated participants, along with robust gains in nasal congestion and total symptom scores, highlighting a differentiated efficacy profile with quarterly dosing (GLOBE NEWSWIRE)
The company has laid out a clear Phase 3 development roadmap, securing End-of-Phase 2 FDA interactions in mid-2026 and planning to initiate registrational trials in both severe asthma and CRSwNP in the first quarter of 2027, demonstrating regulatory alignment and operational readiness (GLOBE NEWSWIRE)
Upstream Bio incurred a net loss of $39.7 million in Q2 2026, with research and development expenses of $36.1 million, underscoring a high cash burn rate that may necessitate future capital raises and potential shareholder dilution (GLOBE NEWSWIRE)
Enrollment in the Phase 2 VENTURE COPD trial was only completed in June 2026, with efficacy data now delayed to the second half of 2027, extending clinical timelines and heightening development risk in its third core indication (GLOBE NEWSWIRE)
The company’s valuation is heavily dependent on verekitug as its sole TSLP receptor antagonist in development across three indications, exposing investors to binary Phase 3 trial outcomes and regulatory uncertainties without a diversified pipeline (GLOBE NEWSWIRE)
Data summarised monthly by Lightyear AI. Last updated on 20 Aug 2026.
Upcoming events
No upcoming events
Funds containing UPB
AllUSDGBPEUR
Fund name | Fund size | $UPB weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.03% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.03% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.